Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of genakumab injection in connective tissue disease-associated interstitial lung disease
CTR20233643Phase 2Active
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of genakumab in connective tissue disease-associated interstitial lung disease (CTD-ILD), interstitial lung disease (ILD), pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Mar 2024; status: active.
02
Drugs
genakumab
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)interstitial lung disease (ILD)pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on CTR20233643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233643.